Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.99
-0.03 (-0.58%)
Apr 23, 2026, 11:58 AM EDT - Market open
Company Description
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 489 |
| CEO | Michael Raab |
Contact Details
Address: 400 Fifth Avenue, Suite 210 Waltham, Massachusetts 02451 United States | |
| Phone | 510 745 1700 |
| Website | ardelyx.com |
Stock Details
| Ticker Symbol | ARDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001437402 |
| CUSIP Number | 039697107 |
| ISIN Number | US0396971071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Raab | President, Chief Executive Officer and Director |
| James P. Brady | Chief Human Resources Officer |
| Eric Duane Foster | Chief Commercial Officer |
| Rajani Dinavahi M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Feb 24, 2026 | 144 | Filing |
| Feb 23, 2026 | 144/A | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |